Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Thrombosis and Haemostasis Année : 1987

Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization.

Résumé

Cyclic nucleotide phosphodiesterase inhibitors (HL-725, RO 15-2041, cilostamide, quercetin and MY-5445) potently inhibit human platelet aggregation induced by ADP. In parallel, PDE inhibitors inhibit the increase in cytoplasmic free Ca2+ evoked by ADP, as measured with the fluorescent probe quin 2. The inhibition of ADP-induced aggregation and rise in [Ca2+]i is potentiated by PGE1 which stimulates adenylate cyclase and is inhibited by adrenaline which inhibits adenylate cyclase. PDE inhibitors increase human platelet cAMP levels in the presence of low concentrations of PGE1. It is suggested that PDE inhibitors prevent platelet aggregation by raising cAMP levels and by subsequent inhibition of cytoplasmic free Ca2+ mobilization.
Fichier non déposé

Dates et versions

hal-02516526 , version 1 (23-03-2020)

Identifiants

  • HAL Id : hal-02516526 , version 1

Citer

Francois Lanza, Alain Beretz, A Stierle, G Corre, Jean-Pierre Cazenave. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization.. Thrombosis and Haemostasis, 1987, 45 (5), pp.477-484. ⟨hal-02516526⟩

Collections

SITE-ALSACE
13 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More